Eczema drug trial could mean fewer shots for patients

NCT ID NCT06526182

Ongoing Disease control Sponsor: Almirall, S.A. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests the drug lebrikizumab in 520 adults and teens (ages 12+) with moderate-to-severe eczema. Part 1 looks at how well the drug improves skin symptoms over 24 weeks. Part 2 compares a new dosing schedule (every 12 weeks) to the current one (every 4 weeks) to see if it works just as well. The goal is to find a more convenient treatment option that still controls the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DERMATITIS, ATOPIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema dermatitis Eczema Skin Diseases, Eczematous skin disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DERMATITIS, ATOPIC ECZEMA

Contacts and locations

Show contact details

Locations

Consorci Hospital General Universitari de València

Valencia, Spain
Hospital General Universitario Dr. Balmis

Alicante, Spain
Hospital Universitario Clínico San Cecilio

Granada, Spain
Hospital del Mar - Parc de Salut Mar

Barcelona, Spain